N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE
生物活性体内研究 用途与合成方法 MSDS N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE价格(试剂级) 上下游产品信息
| 中文名称 | N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE |
|---|---|
| 中文同义词 | JPM 565 乙基酯;化合物 T15626 |
| 英文名称 | N-[[L-trans-3-(Ethoxycarbonyl)oxiran-2-yl]carbonyl]-L-leucyl-3-(p-hydroxyphenyl)ethylamide |
| 英文同义词 | JPM 565-OEt;N-[[L-trans-3-(Ethoxycarbonyl)oxiran-2-yl]carbonyl]-L-leucyl-3-(p-hydroxyphenyl)ethylamide;XSC-2;JPM-OEt;(2S,3S)-3-[[[(1S)-1-[[[2-(4-Hydroxyphenyl)ethyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-2-oxiranecarboxylic acid ethyl ester;JPM 565 ethyl ester;2-Oxiranecarboxylic acid, 3-[[[(1S)-1-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-, ethyl ester, (2S,3S)-;JPM OEt,JPMOEt |
| CAS号 | 262381-84-0 |
| 分子式 | C20H28N2O6 |
| 分子量 | 392.45 |
| EINECS号 | |
| 相关类别 | Pepetides;peptides |
| Mol文件 | 262381-84-0.mol |
| 结构式 | ![N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE 结构式](CAS/20200515/GIF/262381-84-0.gif) |
N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE 性质
| 储存条件 | 4°C, protect from light |
|---|---|
| 溶解度 | DMSO:125.0(最大浓度 mg/mL);318.51(最大浓度 mM) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
JPM-OEt 是一种广谱的半胱氨酸组织蛋白酶 (cysteine cathepsin) 抑制剂。JPM-OEt 在活性位点共价结合，并且不可逆地抑制半胱氨酸组织蛋白酶家族。具有抗肿瘤活性。
JPM-OEt (50 mg/kg; i.p.; daily for 30 days) reduces tumor cathepsin B activity significantly.
JPM-OEt (50 mg/kg; i.p.; twice daily for 4 weeks) leads to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis.
JPM-OEt (50 mg/kg; i.p.; daily from 63 to 98 days) causes a significant delay in the increase of tumour burden during the first 2 weeks of treatment.
| Animal Model: | Female mice of a transgenic mouse |
| Dosage: | 50 mg/kg |
| Administration: | i.p.; daily from 63 to 98 days |
| Result: | Caused a significant delay in the increase of tumour burden during the first 2 weeks of treatment. However, on days 84, 91 and 98 no significant differences between both groups could be detected. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/08/19 | HY-102087 | JPM-OEt | 1 mg | 2181元 | |
| 2024/08/19 | HY-102087 | N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE JPM-OEt | 262381-84-0 | 5 mg | 4800元 |